A Multicenter Phase II Clinical Trial Assessing the Efficacy of the Combination of Lapatinib and Capecitabine in Patients With Non Pretreated Brain Metastasis From HER2 Positive Breast Cancer.

Trial Profile

A Multicenter Phase II Clinical Trial Assessing the Efficacy of the Combination of Lapatinib and Capecitabine in Patients With Non Pretreated Brain Metastasis From HER2 Positive Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2013

At a glance

  • Drugs Capecitabine (Primary) ; Lapatinib (Primary)
  • Indications Advanced breast cancer; Brain metastases
  • Focus Biomarker; Therapeutic Use
  • Acronyms LANDSCAPE
  • Most Recent Events

    • 29 Sep 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
    • 29 Sep 2012 Primary endpoint 'Objective-clinical-response-rate' has been met.
    • 06 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top